Catalog Advanced Search

Search by Category
Search in Packages
Search by Format
Search by Type
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Keyword
Sort By
  • Contains 2 Component(s) Recorded On: 10/29/2021

    Webinar hosted by the Liver Fibrosis Special Interest Group on October 29, 2021.

    This webinar coincided with PSC Awareness Day. We highlighted PSC in terms of disease pathology and curative options open to patients suffering from PSC. The goals of the webinar are obtaining both basic and clinical scientific updates on the work and treatment strategies focusing on potential anti-fibrotic therapies and to shed light on PSC progression and the PSC Partners Seeking a Cure work.

    Ricky Safer

    Ricky Safer is a PSC patient, Founder and CEO of PSC Partners Seeking a Cure, a 501(c)(3) non-profit organization launched in 2005 with the mission to provide education and support to PSC patients, families, and caregivers, as well as to raise funds to research causes, treatments, and cures for primary sclerosing cholangitis.  PSC Partners, in collaboration with the NIH, created a patient-reported Registry that currently houses the data of 1900 participants. With its Canadian affiliate, PSC Partners has awarded over $4 million in grants to support promising international PSC research. To facilitate research, PSC Partners obtained a disease-specific unique ICD-10 code for PSC. In 2020, PSC Partners presented to the FDA and drug developers an all-day Externally-Led Patient Focused Drug Development (PFDD) Meeting to bring the patient voice into drug development. In 2019, PSC Partners was awarded the Chan-Zuckerberg Initiative Rare As One grant to create a collaborative research network.

    Safer serves on the steering committees of the PSC Forum and the Childhood Liver Disease Research Network Patient Advocacy Group, and on the External Advisory Committee of the Mayo Clinic Chris M. Carlos and Catharine-Nicole Jockisch Carlos Endowment.  She has presented at the AASLD Emerging Trends Conference “Cholangiopathies:  The Dawn of Curative Treatments?”, Childhood Liver Disease Research Network (CHiLDReN) Meeting, Consortium for Autoimmune Liver Diseases (CALiD) Meetings, PSC Forum Meetings and the Center for Autoimmune Liver Disease (CALD) Symposia. She contributed Registry data and was an author for posters at the Liver Meeting and at the EASL Meeting.  She authored articles in Healio Hepatology to highlight the differences between PSC and PBC following the PBC name change. She was an author of several articles published on Registry data and on PSC PRO’s that appeared in AASLD Hepatology, Clinical Gastroenterology and Hepatology, and Hepatology Communications.  She is profoundly committed to PSC Partners, which includes thousands of PSC patients, and a community of unwavering PSC researchers who are tirelessly working towards treatments and a cure.

    Robert C. Huebert

    Robert C. Huebert, MD is Associate Professor of Medicine at Mayo Clinic in Rochester, MN. He is a transplant hepatologist and is the current Program Director for the Advanced Transplant Hepatology Fellowship Program. He is also an NIH-funded physician-scientist with primary research interests in cholestatic fibrogenesis and epigenetics. Additionally, his laboratory has done innovative studies in biliary regenerative medicine including work on pluripotent stem cell-derived cholangiocytes, biliary biostents, and mesenchymal stromal cell therapy for biliary pathologies.

    Dr. Huebert is an Associate Editor for American Journal of Physiology: GI and Liver Physiology and serves as an editorial board member for Hepatology. He has also served on the American Association for the Study of Liver Diseases (AASLD) Research Awards Committee and was Chair of the Abstract Review Committees for AASLD and DDW in Molecular Biology and Stem Cell Biology.

    Cynthia Levy

    Cynthia Levy, MD, FAASLD is a Professor of Medicine in the Division of Digestive Health and Liver Diseases and is the Associate Director of the Schiff Center for Liver Diseases at the University of Miami. She was awarded the Arthur Hertz Endowed Chair in Liver Diseases. Dr. Levy received her M.D. from Universidade Federal do Rio de Janeiro (UFRJ). She completed house staff training both at her home University and subsequently at University of Miami/Jackson Memorial Hospital, in Miami, FL. Dr. Levy completed her 3-year Gastroenterology Fellowship at Mayo Clinic in Rochester, Minnesota, and a 1-year Transplant Hepatology Fellowship at University of Florida, in Gainesville, FL.

    Dr. Levy’s clinical research program focuses on clinical trial development and conduct for autoimmune and cholestatic liver diseases, and in the study of porphyrias. Dr. Levy is a member of the steering committee for the International Primary Sclerosing Cholangitis Study group (IPSCSG) and serves as the Chair for the TARGET-Primary Biliary Cholangitis (PBC) national registry. She is a steering committee member for the Cholestatic and Autoimmune Liver Diseases SIG in AASLD and serves as an advisor for several patient support groups and Foundations. Dr. Levy’s expertise is recognized internationally.

    Heather L. Francis (Moderator)

    Heather L. Francis, PhD, FAASLD is an expert in cholangiocyte biology and cholestatic liver disease with a specific focus on the paracrine role of mast cells during liver damage. Her work has demonstrated a direct relationship between cholangiocytes and mast cells and shown that mast cells drive liver disease progression, and specifically fibrosis. Dr. Francis has shown that treatment with OTC drugs block mast cell migration and activation and subsequently, ameliorate liver damage. During her time as an independent researcher, Dr. Francis has contributed 17 senior author original manuscript publications, including 7 articles in Hepatology.

    Professor Francis currently serves on the editorial/advisory board member for major journals such as Hepatology and is an Associate Editor for Seminars in Liver Disease. She is currently on the steering committee for the Liver Fibrosis Special Interest Group and a member of the Basic Science Research Committee for the American Association for the Study of Liver Diseases (AASLD). Dr. Francis is currently serving as the chair of the Hepatobiliary Pathophysiology NIH CSR study section (2020-2022). She is the lead Principal Investigator on two NIH NIDDK funded awards regarding the role of mast cells in both cholestatic liver injury and non-alcoholic fatty liver disease. Dr. Francis is also a VA Research Career Scientist and oversees an active VA Merit. In the past, Dr. Francis was an awardee of a PSC Partners Seeking a Cure Research grant and continues to serve this organization as an ad-hoc grant reviewer. As a prolific educator, she has mentored over 50 trainees from high school students to undergraduate, medical, Masters’ and PhD students, clinical residents/fellows, postdoctoral research fellows, and faculty at Assistant/Associate Professor rank from Indianan University.

  • Product not yet rated Contains 1 Component(s) Recorded On: 10/20/2021

    Webinar hosted by the AASLD President on Wednesday, October 20.

    This 60-minute discussion, held Wednesday, October 20th and hosted by AASLD President, Dr. Ray Chung, FAASLD of Massachusetts General, included interviews with NAFLD/NASH experts, Dr. Mary Rinella, FAASLD of Northwestern University and Dr. Anna Mae Diehl, FAASLD of Duke University. Our experts delved into how they manage their practices in fatty liver, how their institutions and multidisciplinary teams work together, diagnostic and treatment solutions to NAFLD, and more.

    This webinar is the first of a new program, AASLD's Thought Leaders Series: How I Manage My Practice. These webinars will feature well-known leaders providing important clinical insights around specific liver conditions and a first-hand account of their experiences. 

    Anna Mae Diehl

    Anna Mae Diehl, MD, FAASLD is currently the Florence McAlister Professor of Medicine at Duke University.  She is a physician scientist and academic hepatologist.  Her lab-based research activities focus on basic mechanisms of liver repair and complement her translational/clinical research programs in alcoholic- and nonalcoholic fatty liver disease.  In the past two years, Dr. Diehl she has co-authored ten peer-reviewed manuscripts on these topics.

    Her basic research program has enjoyed uninterrupted NIH RO1 support since 1990 and she has been the Principal Investigator for the NASH CRN UO1 clinical research program at Duke since its inception over 15 years ago. Dr. Diehl’s research contributions to the fields of regenerative medicine, alcohol-related liver disease and NAFLD have been acknowledged by election for membership in the American Society for Clinical Investigation, Interurban Clinical Club, Association of Academic Professors and Johns Hopkins University Society of Scholars, as well as awards such as an NIH/NIAAA Merit Award, the NIAAA Mendelson Award, the Duke Distinguished Faculty Award, and the AASLD Distinguished Scientific Achievement Award. 

    Dr. Diehl has been an associate editor/editorial board member for major journals such as HEPATOLOGY, Gastroenterology, GUT, The American Journal of Physiology, The Journal of Clinical Investigation, Nature Reviews, and eLife.  In addition, she has served as a standing member of several NIH study sections and scientific advisory councils for NIDDK, NCI, NIAAA, the American Liver Foundation, the Alcoholic Beverage Medical Research Foundation, NIDDK Digestive Disease Centers at Baylor, USC and U Pittsburgh, and NIAAA Alcohol Research Centers at U Louisville and the Cleveland Clinic.  

    Mary E. McCarthy Rinella

    Mary E. Rinella, MD is a Professor of Medicine at Northwestern University Feinberg School of Medicine and is the Director of the Northwestern Fatty Liver Program. She received her medical degree from the University of Illinois.  She completed her residency training in Internal Medicine at the University of Chicago and her fellowship in Gatroenterology and Hepatology at Northwestern University, where she remains on faculty.  She studied basic mechanisms of steatohepatitis with the support of the American Gastroenterological Association and the National Institute of Health for 10 years.  Currently her focus is in clinical research in the area of non-alcoholic fatty liver disease/NASH both before and after liver transplantation. Her primary clinical focus within the NASH realm is on the associations between NASH and other metabolic co-morbidities, emerging NASH therapeutics and the recurrence of NASH after liver transplantation.  She established a multicenter consortium to study the risk factors for liver disease recurrence and outcomes of patients transplanted for NASH cirrhosis (NailNASH Consortium).  Dr. Rinella is actively involved in the American Association for the Study of Liver Diseases where she currently serves as Councilor-at-large on the Governing Board.  She has held several national leadership roles in the field of NAFLD including Chair of the AASLD NAFLD Special Interest Group (SIG) and most recently as Chair of the AASLD NASH Task Force.  As Chair of the NASH Task Force, she is charged with fostering research collaboration and advancing best practice through collaboration with other medical societies, federal agencies and patient advocacy organizations.

    Raymond Chung (Moderator)

    Raymond Chung, MD, FAASLD is Director of Hepatology and the Liver Center, Vice Chief of Gastroenterology and the Kevin and Polly Maroni Research Scholar atMassachusetts General Hospital. He has been an internationally recognizedresearcher in the areas of HCV virology and pathogenesis. He directs an NIHCooperative Center for Human Immunology centered on HCV, and is co-PI of theHarvard HBV Consortium of the NIH HBV Research Network. He is contact PI of hisDivisional T32 Training Grant, and holds several NIH R01 grants and an NIH K24Mentorship Award.

    He was recently Associate Editorof HEPATOLOGY and has previously served as a Councilor at Large for the AASLD.He has also served as co-Chair of the AASLD/IDSA HCV Guidance panel which ischarged with issuing treatment recommendations for hepatitis C. He has authoredmore than 300 original articles, reviews, and editorials.

  • Contains 4 Component(s), Includes Credits Recorded On: 10/19/2021

    Cirrhosis Quality Collaborative (CQC) is a multi-site improvement initiative supporting learning and sharing to improve the care and treatment outcomes of individuals living with cirrhosis.

    DESCRIPTION
    The Cirrhosis Quality Collaborative (CQC) adopts monthly calls and full or half-day learning session events that invite improvement team representatives from all CQC member sites to convene for the purposes of learning and sharing in the pursuit of CQC improvement goals. While specific learning objectives are emergent and shaped by the evolving needs of members over the course of the CQC, common features of these calls include peer-to-peer sharing, relevant care model and change ideas, improvement and implementation strategy, review and analysis of improvement data, and emerging news and resources that are directly relevant to the improvement aims. 

    KEY TOPIC AREA
    Improvement strategies utilized to change processes and systems at participating hospital sites within the CQC learning network. 

    CME INTERNET LIVE ACTIVITY
    Release date:
     October 19, 2021
    Expiration date: October 19, 2021
    Time in internet live activity: up to 1.50 hours

    CME and CE INTERNET ENDURING ACTIVITY (Available)
    Release date: December 20, 2021
    Expiration date: December 19, 2024
    Previously recorded: October 19, 2021
    Time to complete internet enduring activity: up to 1.50 hours

    CREDITS OFFERED
    Continuing Medical Education (CME): For a maximum of 1.50 AMA PRA Category 1 Credits™  
    Continuing Education (CE): For a maximum of 1.50 Contact Hour**  
    You may only earn one Continuing Education Credit type - either CME or CE

    COMPONENTS
    On-demand webinar series comprised of:

    - 1.50 hour session in length
    -Evaluation for CME or CE credit offering 

    DIRECTIONS
    Click "Register" to activate the enduring material. Review all section tabs before you begin. Select session of interest. Complete all components to claim either CME or CE. 

    COPYRIGHT 
    All faculty in this activity have given their permission for publication ©2021 AASLD. 

    CONTACT INFORMATION 
    For questions on CME content or LiverLearning®, contact online_education@aasld.org 
    For questions on CE credit for this enduring material, contact Certificate@AmedcoEmail.com

    **CME AMA PRA Category 1 Credits™ and CE Contact Hours will be available for on-demand/internet enduring activity beginning December 20, 2021.**

    Learning Objectives:

    1. Review our shared CQC vision and improvement objectives
    2. Review registry reports focusing on ascites control data
    3. Gather concrete change ideas for improving ascites control
    4. Connect with peers to exchange ideas and strategies for improvement


    This curriculum was developed for Primary Care Providers and any other healthcare provider interested in liver disease.

    Hepatologists
    Nurses
    Nurse Practitioners
    Physician Assistants
    Fellows/Trainees
    Primary Care Physicians
    Other healthcare providers

    CREDITS OFFERED 
    Continuing Medical Education (CME): For a maximum of 1.50 AMA PRA Category 1 Credits™   
    Continuing Education (CE): For a maximum of 1.50 Contact Hours

    ACCREDITATION AND DESIGNATION STATEMENTS 
    Continuing Medical Education (CME) 
    The American Association for the Study of Liver Diseases (AASLD) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. AASLD designates this enduring activity for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    image

    Continuing Education (Nursing Contact Hours)  
    In support of improving patient care, this activity has been planned and implemented by Amedco LLC and the American Association for the Study of Liver Diseases.  Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Credit Designation Statement – Amedco LLC designates this enduring material activity for a maximum of 1.50 ANCC contact hours for nurses. Learners should claim only the credit commensurate with the extent of their participation in the activity.

    CLAIMING LIVE CME CREDITS 
    Physicians and other health care professionals for a maximum of 1.50 AMA PRA Category 1 Credits™ for this enduring continuing medical education material must completed by November 30, 2021.  

    CLAIMING CME CREDITS 
    Physicians and other health care professionals for a maximum of 1.50 AMA PRA Category 1 Credits™ for this enduring continuing medical education material must completed by December 19, 2024.

    CLAIMING CE CREDITS
    Nurses for a maximum of 1.50 ANCC contact hours for this enduring continuing education material must be completed by December 19, 2024

    DISCLOSURE OF CONFLICTS OF INTEREST 
    AASLD requires all individuals who are in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosures are collected prior to the start of the educational activity. Any potential conflicts of interest that exist are resolved prior to implementation of the activity. All disclosures are made available and communicated to the leaner prior the activity beginning.

    The enduring material organizers, faculty, reviewers and staff have reported the following disclosures:

    Christina Clarke, MHA, BSc
    Faculty/Organizer
    Consulting: Improvement advisor (independent contractor) for the Cirrhosis Quality Collaborative
    Independent Contractor: Improvement advisor (independent contractor) for the Cirrhosis Quality Collaborative

    Audrey Davis-Owino, MRP
    Organizer/Reviewer
    Nothing to disclose

    Fasiha Kanwal, MD, MSHS, AGAF, FAASLD
    Organizer/Reviewer
    Grant/Research Support: Gilead Sciences and Merck 

    Sheila Tynes, MHA, PMP
    Organizer/Reviewer
    Nothing to disclose

    Michael Volk, MD, MSc, FAASLD
    Organizer/Reviewer
    Nothing to disclose 

    Dominique Clayton 
    AASLD Staff
    Nothing to disclose

    Sheryl Morgan 
    Amedco LLC Staff
    Nothing to disclose

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    DISCLAIMER
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

    Acknowledgement of Commercial Support: No commercial support was received for this enduring material activity.


  • Contains 2 Component(s) Recorded On: 10/13/2021

    Webinar hosted by the Nonalcoholic Fatty Liver Disease Special Interest Group on October 13, 2021.

    In this one-hour webinar, learn about the pathophysiology of microbiome and liver disease, microbiome in NASH and microbiome in cirrhosis and other liver conditions.

    Suzanne Devkota

    Suzanne Devkota, PhD is Director of Microbiome Research at Cedars-Sinai Medical Center in Los Angeles and Assistant Professor of Medicine at UCLA, as well as an adjunct investigator at the Joslin Diabetes Center at Harvard Medical School. She completed her doctoral and post-doctoral training at The University of Chicago and Joslin Diabetes Center/Harvard Medical School respectively and is a former Branco Weiss Fellow.

    Professor Devkota has been studying the effect of diet on the gut microbiome and inflammatory diseases for the past 12 years. Investigating the dietary drivers of gut microbiome structure and function in inflammatory bowel diseases and metabolic diseases. More recently, her lab has developed interest in studying the microbial ecology of gut bacterial translocation in the human body. Interest lies in the study of commensal microbes that take advantage of impaired host defenses to turn pathogenic.

    Rohit Loomba

    Rohit Loomba, MD is a Professor of Medicine (with tenure), Director of Hepatology and Vice Chief, Division of Gastroenterology at University of California at San Diego. He is an internationally recognized thought leader in translational research and innovative clinical trial design in nonalcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH) and non-invasive assessment of steatosis and fibrosis using advanced imaging modalities.

    Dr. Loomba is the founding director of the UCSD NAFLD Research Center where his team is conducting cutting edge research in all aspects of NAFLD including non-invasive biomarkers, genetics, epidemiology, clinical trial design, imaging end-points and integrated OMICs using microbiome, metabolome and lipidome.

    Jasmohan S. Bajaj

    Jasmohan S. Bajaj, MBBS, MD, MS, FACG, AGAF, FRCP, FAASLD is Professor of Medicine, Division of Gastroenterology, Hepatology, and Nutrition at Virginia Commonwealth University and Richmond, VA Medical Center in Richmond, VA. He is a Fellow of the American College of Gastroenterology, American Gastroenterological Association, American Association for the Study of Liver Diseases, was elected to the Fellowship of the Royal College of Physicians in London and to the American Society for Clinical Investigation. Dr. Bajaj earned his MBBS from Delhi University at Maulana Azad Medical College. He completed an internship in internal medicine at Delhi University at Maulana Azad Medical College and internal medicine residency at the State University of New York Health Science Center in Brooklyn. He furthered his medical training with a fellowship in gastroenterology and hepatology at the Medical College of Wisconsin Affiliated Hospitals, then went on to earn an MS in epidemiology at the Medical College of Wisconsin in Milwaukee.

    Active in research, Dr. Bajaj has served as a principal investigator or co-investigator for numerous clinical trials in areas such as hepatic encephalopathy, chronic liver disease and microbiome. Dr. Bajaj’s research has been funded through the NIH, US Veterans Affairs, AHRQ, and American College of Gastroenterology. His work has been published in Nature, New England Journal of Medicine, Gastroenterology, Journal of Hepatology, Hepatology, The American Journal of Gastroenterology, and Liver Transplantation, among others. Dr Bajaj is the upcoming Co-Editor in Chief for the American Journal of Gastroenterology and is currently an associate Editor for the Red Journal and Gut Microbes. He is on the editorial board for Journal of Hepatology, Hepatology, and Liver Transplantation. He was a member of the AASLD/EASL Hepatic Encephalopathy Guidelines Writing Committee, is the Chairperson of the Acute-on-Chronic Liver Failure ACG Clinical Guidelines and a member of the AASLD ICU and ACLF Guidance committee. He is also a member of the AASLD Clinical Research Committee. Dr Bajaj is the Chairperson for the North American Consortium for Study of End-Stage Liver Disease and was the immediate Past President of the International Society for Hepatic Encephalopathy and Nitrogen Metabolism.

    Stephen A. Harrison (Moderator)

    Stephen Harrison, MD, FACP, FAASLD earned his medical degree from the University of Mississippi School of Medicine. He completed his internal medicine residency and gastroenterology fellowship at Brooke Army Medical Center and a 4th year advanced liver disease fellowship at Saint Louis University. He is board certified in both Internal Medicine and Gastroenterology.

    Dr. Harrison is a Visiting Professor of Hepatology at the Radcliffe Department of Medicine, University of Oxford. He is internationally known for studies in hepatitis C and non-alcoholic fatty liver disease with over 200 peer reviewed publications in these fields. Dr Harrison currently serves as the Medical Director for Pinnacle Clinical Research and the President of Summit Clinical Research in San Antonio, Texas.

  • Contains 2 Component(s) Recorded On: 09/30/2021

    Webinar hosted by the Membership and Mentorship Committee and Inclusion and Diversity Committee on Thursday, September 30.

    The purpose of this webinar is to present strategies to approach patient and family communication near the end-of-life in the setting of advanced liver disease with a focus on issues related to equity, diversity and inclusion. Patients with advanced liver disease experience high symptom burden, emotional distress, and prognostic uncertainty which makes them particularly vulnerable to suboptimal end-of-life care. In addition, prior work from other serious illnesses has highlighted the influence of cultural background including race, ethnicity, religion, sexual orientation, gender and other forms of identity on patients’ end-of-life care experiences and outcomes. In this webinar we will present a series of case scenarios that highlight the importance of approaching end-of-life communications with cultural humility and strategies to develop patient- and family-centered communication skills that acknowledge their voices, concerns, values, and lived experiences. The webinar will include a panel session, case-based presentations, and audience questions and discussion. The panel will consist of physicians with professional expertise that includes hepatology, palliative care, health services research, and health disparities research, and the intended audience is clinicians who provide care to people with liver diseases and their families and informal caregivers.

    Nneka Ufere

    Nneka N. Ufere, MD is a Transplant Hepatologist in the Division of Gastroenterology within the Department of Medicine at Massachusetts General Hospital and Harvard Medical School in Boston, MA. She attended Washington University in St. Louis School of Medicine where she completed her medical degree in 2012. She completed her residency training in internal medicine at Massachusetts General Hospital, where she also served as a Chief Medical Resident during the 2016-2017 academic year. She completed her Gastroenterology fellowship in 2020 and Transplant Hepatology fellowship in 2021 at Massachusetts General Hospital. She is currently pursuing a Master of Science in Clinical Epidemiology degree at the at the Harvard T. H. Chan School of Public Health.

    Dr. Ufere’s research interests center around palliative and supportive care and informed decision-making with the goal of developing interventions aimed at improving the quality of life and quality of care for patients with advanced liver disease and their caregivers. Her work is currently supported by a Clinical, Translational and Outcomes Research Award from the American Association for the Study of Liver Diseases and the Massachusetts General Hospital Physician Scientist Development Award. She is a past recipient of the NIH Loan Repayment Award, the American College of Gastroenterology Clinical Research Pilot Award and an Advanced/Transplant Hepatology Award from the American Association for the Study of Liver Diseases.

    Christopher Woodrell

    Christopher Woodrell, MD, MS is a health services researcher and board-certified internist and palliative care physician at the Icahn School of Medicine at Mount Sinai in New York City, where he is an appointed Assistant Professor. He is also Staff Physician within the Geriatric Research, Education and Clinical Center (GRECC) at the James J. Peters VAMC in the Bronx, NY. He received his Medical Doctorate, Internal Medicine Training, and Hospice and Palliative Medicine fellowship training at Mount Sinai.

    Dr. Woodrell's career goal is to help improve quality of life experienced by people facing advanced liver disease and liver cancer. His research focus is developing and testing early palliative care interventions for people with hepatocellular carcinoma and their family caregivers. He completed undergraduate training in biochemistry at Swarthmore College in Pennsylvania.

    Arpan A. Patel

    Aran A. Patel, MD, PhD is a transplant hepatologist and health services researcher at the David Geffen School of Medicine at UCLA. He is also a staff physician at the West Los Angeles Veterans Affairs Center and core investigator at the VA Center for the Study of Healthcare Innovation, Implementation and Policy (CSHIIP) in Los Angeles. He performed his residency in Internal Medicine at the Hospital of the University of Pennsylvania, followed by fellowship in gastroenterology at UCLA and fellowship in Transplant Hepatology at Mount Sinai. He completed a PhD in Health Policy and Management at the Fielding School of Public Health at UCLA in 2020. 

    Dr. Patel’s career goal is to ensure that patients with advanced liver disease receive high-value care that optimizes their quality of life. His research goal is to understand ways that principles of palliative care can be integrated in management of these patients and their caregivers.

    Julius Wilder

    Julius Wilder, MD, PhD, is an Assistant Professor of Medicine at Duke University School of Medicine in Durham, North Carolina, and is on faculty at Duke Regional Hospital and the Duke Clinical Research Institute. He received his medical degree from Duke School of Medicine and completed his residency at Duke Hospital. He then completed his fellowships in gastroenterology and transplant hepatology at Duke School of Medicine. Dr. Julius Wilder obtained the first combination MD/PhD in Medical Sociology in the history of Duke University.

    Dr. Wilder studies how fundamental causes of disease like race, gender, education, and wealth contribute to adverse health outcomes and health disparities. His research has highlighted the need for increased minority participation in clinical trials and documented the safety and efficacy of direct-acting antivirals for treating hepatitis C in African Americans. Dr. Wilder is a principal investigator or co-principal investigator on multiple clinical trials in hepatology and has received research awards for his work on social determinants of disparities in gastroenterology and hepatology, including the 2018 AASLD Foundation Clinical, Translational, and Outcomes Research Award.

    Vinay Sundaram (Moderator)

    Vinay Sundaram, MD, MS is atransplant hepatologist at Cedars-Sinai Medical Center, where he serves asassistant medical director of liver transplantation and director of hepatologyoutcomes research. He has been a member of the AASLD since 2009. He is activelyinvolved with numerous committees including the AASLD membership andmentorship committee, chair of the education subcommittee for the clinicalpractice special interest group.  In addition, he is on themembership and professional standards committee for UNOS. His researchinterests include end-stage liver disease, acute on chronic liver failure andpost-transplant outcomes. He has over 100 published manuscripts and abstractsand is on the editorial board for Hepatology Communications. 

    Raymond Chung (Moderator)

    Raymond Chung, MD, FAASLD is Director of Hepatology and the Liver Center, Vice Chief of Gastroenterology and the Kevin and Polly Maroni Research Scholar atMassachusetts General Hospital. He has been an internationally recognizedresearcher in the areas of HCV virology and pathogenesis. He directs an NIHCooperative Center for Human Immunology centered on HCV, and is co-PI of theHarvard HBV Consortium of the NIH HBV Research Network. He is contact PI of hisDivisional T32 Training Grant, and holds several NIH R01 grants and an NIH K24Mentorship Award.

    He was recently Associate Editorof HEPATOLOGY and has previously served as a Councilor at Large for the AASLD.He has also served as co-Chair of the AASLD/IDSA HCV Guidance panel which ischarged with issuing treatment recommendations for hepatitis C. He has authoredmore than 300 original articles, reviews, and editorials.

  • Contains 1 Component(s) Recorded On: 09/29/2021

    Webinar hosted by the American Association for the Study of Liver Diseases and Global Liver Institute on Wednesday, September 29.

    The Non-alcoholic steatohepatitis (NASH) Congressional briefing co-led by The American Association for the Study of Liver Diseases (AASLD) and Global Liver Institute (GLI) focused on establishing a national strategy to advance prevention, treatment, and diagnosis of NASH, the most severe form of nonalcoholic fatty liver disease.

  • Contains 2 Component(s) Recorded On: 09/22/2021

    Webinar hosted by the Public Policy Committee on Wednesday, September 22.

    The Liver Meeting®, held by the American Association for the Study of Liver Diseases, brings together attendees from around the world to exchange the latest research, discuss new developments in treatments and network with others in the field. This year's annual meeting will be held November 12 - 15, 2021. It will be a digital only meeting. This scientific meeting has expanded greatly in the past few years to include opportunities for patients and patient advocates to engage in meaningful participation. There are special presentations that summarize key scientific findings released at the meeting and break down how the information can be useful for patients and advocates in their work and lives. There are also many networking opportunities through the annual patient advocates forum and the patient connection and community lounge. This webinar will provide an opportunity for patients and patient advocates to learn more about AASLD, The Liver Meeting®, patient advocate sessions being planned this year, how they can participate in this year's conference and share any feedback.

    Meena B. Bansal

    Meena B. Bansal, MD, FAASLD is currently Professor of Medicine in the Division of Liver Diseases at the Icahn School of Medicine at Mount Sinai, Deputy Chief Medical Officer for Mount Sinai Health Partners, and Vice President, Population Health for Quality and Efficiency. Dr. Bansal attended Harvard University and then Cornell Medical School. She completed her internship and residency at Cornell Medical School and her Gastroenterology Fellowship at the University of Pennsylvania in 2001.

    Dr. Bansal joined the faculty at Mount Sinai in 2001 and from 2002-2009 she served as Transplant Hepatology Fellowship Director, leading one of the largest transplant hepatology fellowships in the United States. While remaining clinically active, she developed an NIH-funded basic research program focusing on understanding underlying molecular mechanisms of liver fibrosis and stellate cell biology in an effort to develop novel anti-fibrotic therapies. Her current research interests focus on the impact of HIV on hepatic inflammation and fibrosis. She became the Director of Translational Research in the Division of Liver Diseases in 2013 and has been principal investigator for numerous clinical trials ranging from HCV to NASH. In 2013, she became the Medical Director of all Hospital-based Clinics at Mount Sinai. In this latter role she developed an interest in population health and the challenges of the evolving health care landscape. Over the past 5 years, her focus has also been on building a population health infrastructure that will allow a large academic health system to be successful in value-based care.

    Karen Hoyt

    Karen R. Hoyt is a patient advocate at ihelpc.com, Your Best Friend’s Guide to Chronic Liver Disease. She is also a Language Arts teacher who was diagnosed with chronic liver disease, hepatocellular carcinoma, and is a liver transplant recipient. She is the author of The Liver Loving Diet.

    After successful treatment for hepatitis C in 2012, she began a website to encourage and inform patients, which led to other speaking and writing engagements about her experience living with liver disease. When she was diagnosed with hepatocellular carcinoma, she completed her book, The Liver Loving Diet to provide health and nutritional tips for those with CLD. While receiving chemotherapy treatments, she began training for the World Transplant Games. After her life saving liver transplant, she went on to receive the gold medal in cycling in her division in Malaga, Spain.

    Karen serves on the American Association for the Study of Liver Disease (AASLD) COVID-19 task force and other committees as a patient advocate. She is a graduate of and speaker to the Global Liver Institute’s (GLI) Academy. She is the Vice President and Co-Founder of Transplant Recipients International (TRIO) Oklahoma chapter, a member of National Viral Hepatitis Roundtable (NVHR), serves as a committee member for the World Transplant Games Federation (WTGF) and a member of the World Hepatitis Alliance. She has coauthored peer reviewed articles for such journals as HEPATOLOGY and Clinical Liver Disease.

    Ryan Clary (Moderator)

    Ryan Clary is a non-profit executive with over 25 years of experience in HIV, viral hepatitis and health care advocacy. Most recently, he served as the Executive Director of the National Viral Hepatitis Roundtable where he developed and oversaw the organization’s public policy, programmatic, communications and fundraising strategies.

    Since 2018, Ryan has served as a consultant with End the Epidemics: Californians Mobilizing to End HIV, viral hepatitis, STIs and overdose. In that role, Ryan coordinates and provides strategic input to the coalition of over 300 organizations committed to these epidemics. He also consults with the San Diego Hepatitis C Task Force by providing technical assistance to stakeholders developing a strategic plan to eliminate hepatitis C in San Diego and with the California TB Controllers Association to strengthen and grow the Coalition for a TB-free California.

    In April 2021, Ryan was named co-chair of the Los Angeles County Hepatitis C Task Force. In August 2021, he was selected as a member of the Hep B United National Advisory Board.

  • Contains 2 Component(s) Recorded On: 09/02/2021

    Webinar hosted by the Pediatric Liver Disorders Special Interest Group on September 2, 2021.

    Biliary atresia (BA) is a rapidly progressive inflammatory fibro-obliterative process affecting intra and extra hepatic bile ducts. BA is the most common indication for liver transplantation in children, however the etiopathogenesis is not completely understood. This one hour webinar will summarize genomics in BA, current diagnostic algorithms and novel prognosticators for BA, and long term outcomes of BA. Learners will gain understanding of current practices and future directions in etiopathogenesis and outcomes of BA.

    Kathleen M. Loomes

    Kathleen M. Loomes, MD, FAASLD is a Professor of Pediatrics in the Division of Gastroenterology, Hepatology and Nutrition at The Children’s Hospital of Philadelphia (CHOP) and the University of Pennsylvania Perelman School of Medicine. Dr. Loomes is Director of the Fred and Suzanne Biesecker Pediatric Liver Center at The Children’s Hospital of Philadelphia. She is engaged in clinical and translational research focused on pediatric cholestatic liver diseases, such as biliary atresia, Alagille syndrome and PFIC. 

    Dr. Loomes has served as an editorial board member for HEPATOLOGY and Cellular and Molecular Gastroenterology and Hepatology. In the AASLD, she is a past Chair of the Pediatric Special Interest Group and a current member of the Nominations Committee. Dr. Loomes has also served as a standing member of the Hepatobiliary Pathophysiology Study Section for NIH (2016-20). Dr. Loomes is the Principal Investigator at CHOP for the NIDDK-funded Childhood Liver Disease Research Network and the Pediatric Acute Liver Failure Immune Response Network. Her primary research interests are in the genetic susceptibility to biliary atresia and genetic modifiers of the clinical phenotype in Alagille syndrome. Dr. Loomes is the PI of the Pediatric GI T32 at CHOP and Director of Fellows’ Research for the Division of Gastroenterology, Hepatology and Nutrition. 

    Sanjiv Harpavat

    Sanjiv Harpavat, MD, PhD is an Assistant Professor at Baylor College of Medicine and Texas Children’s Hospital. He is a pediatric gastroenterologist with special interests in neonatal cholestasis, genetic causes of liver disease such as progressive familial intrahepatic cholestasis and Wilson disease, liver transplantation, and non-alcoholic fatty liver disease. His clinical and translational research focuses on the serious liver condition biliary atresia (BA). Dr. Harpavat leads an NIH-funded multi-hospital screening initiative for BA, as well as clinical trials of novel medications to help improve outcomes in BA after the Kasai operation.

    Saul J. Karpen

    Saul J. Karpen, MD, PhD, FAASLD is pediatric hepatologist, Professor of Pediatrics, Raymond F. Schinazi Distinguished Biomedical Chair, Chief of the Division of Pediatric Gastroenterology, Hepatology, and Nutrition at Emory University School Medicine/Children’s Healthcare of Atlanta. The overarching aim of his research is to understand cholestasis, with the goal of discovering and implementing rational molecular targets, focusing upon nuclear receptors and transporters. Recent research along these lines includes discovering genetic contributions to biliary atresia (BA; PKD1L1 and other genes) and use of IBAT inhibitors in global clinical studies of BA and other cholestatic diseases of childhood. On a national and international basis, he is engaged in leadership of the Liver Forum’s Pediatric Cholestatic Disease Working Group and two NIDDK-supported consortia for liver disease: ChiLDReN and NASH CRN.

    Krupa R. Mysore (Moderator)

    Krupa R. Mysore, MD, MS is an Assistant Professor of Pediatrics, Section of Gastroenterology, Hepatology and Nutrition, Texas Children’s Hospital, Baylor College of Medicine. Her clinical and research interests are in pediatric liver diseases such as biliary atresia and liver transplantation. She is a board-certified transplant hepatologist and has a master’s degree in Clinical Investigation. Her laboratory work focuses on basic and translational projects designed to establish how immune dysregulation in chronic liver disease alters hosts susceptibility to infection. She is a recipient of the AASLD 2019 Clinical, Translational and Outcomes Research Award.

    Dr. Mysore is a member of the Pediatric Liver Disorders, Liver Transplantation and Surgery, and Cholestatic and Autoimmune Liver Diseases Special Interest Group. She has served previously on executive committee of American Society of Transplantation and research Subcommittee of The Society for Pediatric Liver Transplant. She serves as site PI of national multicenter pediatric transplant clinical trial. Her recent publications related to my clinical and research interests includes Mysore KR, Shneider BL, Harpavat S. Biliary Atresia as a Disease Starting In Utero: Implications for Treatment, Diagnosis, and Pathogenesis. J Pediatr Gastroenterol Nutr. 2019 Jul 22.doi: 10.1097/MPG.0000000000002450 and Mysore KR, Phan TL, Himes RW, Schady D, Eldin KW, Prusty BK, Munoz FM. Human Herpesvirus 6 Infection in Pediatric Liver Transplantation: Single-Center Study of Incidence, Outcomes, and Management. J Pediatric Infect Dis Soc. 2021 May 28;10(5):599-606. doi: 10.1093/jpids/piaa166. PMID: 33491073; PMCID: PMC8163056.

  • Contains 2 Component(s) Recorded On: 07/27/2021

    Webinar hosted by the Nonalcoholic Fatty Liver Disease Special Interest Group on July 27, 2021.

    In this webinar, you will learn how to describe nonalcoholic fatty liver disease (NAFLD) as it relates to genes in animal and human models, their role, function and related pathways. Also, the focus on NAFLD-related genes in human studies and their relationship to disease severity. Lastly, can you use the genes in a precision medicine approach?

    Silvia Sookoian

    Silvia Sookoian, MD, PhD, FAASLD is head of Clinical and Molecular Hepatology Department, Institute of Medical Research IDIM-National Scientific and Technical Research Council (CONICET), School of Medicine, University of Buenos Aires. She is also the Vice-Chair of Institute of Medical Research, IDIM-CONICET, School of Medicine, University of Buenos Aires. Dr. Sookoian received her medical degree with honors in the University of Buenos Aires, Scholl of Medicine (magna cum laude). She completed her residency in Internal Medicine in Cosme Argerich Hospital Associated to the University of Buenos Aires. Argentina. She received her PhD degree in Molecular Medicine in the University of Buenos Aires. Argentina. She has been in clinical practice since 1987 (Clinical Training Board certificated in Internal Medicine; Fellowship in Hepatology). She received training in Hepatology (Hepatology Centers of Excellence Program Sweden), GI–Liver pathology (Armed Forces Institute of Pathology, Washington DC), and genetics of complex diseases (Cold Spring Harbor Laboratories USA and Wellcome Trust Advanced Courses). She was awarded as Fellow of the American Association for the Study of Liver Diseases (FAASLD), which recognizes superior professional achievement in liver research and practice.

    Dr. Sookoian’s current clinical and translational research is focused on genetic, epigenetic, and molecular mechanisms implicated in non-alcoholic fatty liver disease pathogenesis and disease progression. She is involved in both clinical and basic research. She co-authored 172 peer-reviewed on manuscripts on the field of liver diseases. She was involved in pioneer studies on genetics, epigenetics, and tissue microbiome of NAFLD, and the use of OMICs resources to understand the disease biology.  

    Yaron Rotman

    Yaron Rotman, MD, MSc, FAASLD is a clinical investigator and acting chief of the Liver and Energy Metabolism Section in the Liver Diseases Branch of NIDDK. He received his MD and MSc in Neurophysiology degrees from the Hebrew University Hadassah Medical School in Jerusalem, Israel. He subsequently trained in Internal Medicine and Gastroenterology and Hepatology at the Rabin Medical Center in Petach-Tiqva, Israel, before joining the NIDDK Liver Diseases Branch as a fellow, and subsequently as a principal investigator.

    Dr. Rotman’s research focuses on mechanistic questions in non-alcoholic fatty liver disease (NAFLD), the most common liver disorder in the western world. He is utilizing mechanistic clinical trials, human genetics, animal models and in vitro systems to understand mechanisms of hepatic fat accumulation and associated injury. 

    Luca Valenti

    Luca Vittorio Valenti, MD, PhD is an associate professor of Internal Medicine and physician scientist for the Department of Transfusion Medicine and Hematology at Fondazione IRCCS Ca’ Granda Ospedale Policlinico Milano, Italy. His main research interest is understanding the molecular basis of metabolic liver diseases, in particular FLD, iron overload disorders and liver cancer, and to apply these discoveries to the clinical management of patients, through the identification of novel biomarkers, therapeutic strategies and clinical algorithms, in a personalized medicine approach. In collaboration with his international network, he has recently discovered new genetic determinants of FLD. In the iron field, he contributed to establishing the role of body iron accumulation in the pathogenesis of metabolic and cardiovascular complications of insulin resistance, and the therapeutic utility of iron depletion. He uses a variety of tools ranging from epidemiological studies in large cohort of individuals with liver biopsies to human and molecular genetics to understand how a gene mutation results into a phenotype.

    Prof. Valenti has served as reviewer for several international Journals (>60) including New England Journal of Medicine, The Lancet, Gastroenterology, Gut, Journal of Clinical Investigation, HEPATOLOGY, Journal of Hepatology, Nature Communications, Circulation, Diabetes, Blood, several Scientific Societies (EASL, AISF), European Institutions. Since 2019, he is Honorary Member of Institute of Hepatology at the King’s College of London, the Liver Trust. He is considered an opinion leader in the field of metabolic liver diseases, as testified by invited talks and moderations of scientific sessions in scientific meetings and seminars in Italy, Europe, Asia, and the USA.

    Anna Mae Diehl (Moderator)

    Anna Mae Diehl, MD, FAASLD is currently the Florence McAlister Professor of Medicine at Duke University.  She is a physician scientist and academic hepatologist.  Her lab-based research activities focus on basic mechanisms of liver repair and complement her translational/clinical research programs in alcoholic- and nonalcoholic fatty liver disease.  In the past two years, Dr. Diehl she has co-authored ten peer-reviewed manuscripts on these topics.

    Her basic research program has enjoyed uninterrupted NIH RO1 support since 1990 and she has been the Principal Investigator for the NASH CRN UO1 clinical research program at Duke since its inception over 15 years ago. Dr. Diehl’s research contributions to the fields of regenerative medicine, alcohol-related liver disease and NAFLD have been acknowledged by election for membership in the American Society for Clinical Investigation, Interurban Clinical Club, Association of Academic Professors and Johns Hopkins University Society of Scholars, as well as awards such as an NIH/NIAAA Merit Award, the NIAAA Mendelson Award, the Duke Distinguished Faculty Award, and the AASLD Distinguished Scientific Achievement Award. 

    Dr. Diehl has been an associate editor/editorial board member for major journals such as HEPATOLOGY, Gastroenterology, GUT, The American Journal of Physiology, The Journal of Clinical Investigation, Nature Reviews, and eLife.  In addition, she has served as a standing member of several NIH study sections and scientific advisory councils for NIDDK, NCI, NIAAA, the American Liver Foundation, the Alcoholic Beverage Medical Research Foundation, NIDDK Digestive Disease Centers at Baylor, USC and U Pittsburgh, and NIAAA Alcohol Research Centers at U Louisville and the Cleveland Clinic.  

  • Contains 2 Component(s) Recorded On: 07/13/2021

    Webinar hosted by the Public Health/Health Care Delivery on July 13, 2021.

    There is increasing interest to integrate palliative care (PC) within routine practice of decompensated cirrhosis to enhance and inform clinical care. It has shown to improve patient- provider communication, provider awareness of symptoms, tailored symptom management enhance quality of life, ultimately with a better end of life care. There is minimal knowledge on what key elements of PC can inform care, particularly if advance care planning (ACP) has a role to play within Transplant Evaluation. 

    Arpan A. Patel

    Aran A. Patel, MD, PhD is a transplant hepatologist and health services researcher at the David Geffen School of Medicine at UCLA. He is also a staff physician at the West Los Angeles Veterans Affairs Center and core investigator at the VA Center for the Study of Healthcare Innovation, Implementation and Policy (CSHIIP) in Los Angeles. He performed his residency in Internal Medicine at the Hospital of the University of Pennsylvania, followed by fellowship in gastroenterology at UCLA and fellowship in Transplant Hepatology at Mount Sinai. He completed a PhD in Health Policy and Management at the Fielding School of Public Health at UCLA in 2020. 

    Dr. Patel’s career goal is to ensure that patients with advanced liver disease receive high-value care that optimizes their quality of life. His research goal is to understand ways that principles of palliative care can be integrated in management of these patients and their caregivers.

    Manisha Verma (Moderator)

    Manisha Verma, MD, MPH, currently serves as the Director of Research at the Department of Digestive Diseases and Transplantation at Einstein Healthcare Network, Philadelphia, and as the Assistant Professor of Medicine, Research at Sidney Kimmel Medical College. Her program of research focuses on patient centered outcomes research (PCOR) within Hepatology and beyond.  She and her team received a 15 million research award from the Patient Centered Outcomes Research Institute to conduct a multi-site cluster randomized study to compare two models of palliative care delivery for ESLD. She has contributed to advances in knowledge of clinical applications of Health Services Research, specifically in the areas of clinical integration of patient reported outcomes assessments,  integrated care models (palliative care and behavioral health), and population-based health approaches. 

    In her role, she is responsible for promoting and facilitating leading edge research, including collaborative and interdisciplinary research, in areas related to the mission of the Department (to advance patient care, education and new treatments for liver diseases). She serves as the Steering Committee member for the American Association for Study of Liver Diseases (AASLD) Public Health / Healthcare Delivery Group and as the Vice Chair for the Education Subcommittee. Dr. Verma has won both the Albert Einstein Society Innovative Awards and Albert Einstein Society Research Awards as a Principal Investigator since 2015 onwards.  The studies supported from these awards have led to development of a PCOR Pillar within the Department. 

    Brett E. Fortune (Moderator)

    Brett E. Fortune, MD, MSc, is a transplant hepatologist who works at New York Presbyterian/Weill Cornell for the Center for Liver Disease and Transplantation. Dr. Fortune has a clinical focus to provide excellent care for patients with advanced liver disease and those who need or have received liver transplantation.

    Dr. Fortune’s research interests include clinical outcomes related to complications of cirrhosis and portal hypertension as well as quality improvement in the care of patients with cirrhosis or those who have received a liver transplant.